A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease

被引:31
|
作者
Patchett, Stephanie [1 ]
Lv, Zongyang [2 ]
Rut, Wioletta [3 ]
Bekes, Miklos [1 ,4 ]
Drag, Marcin [3 ]
Olsen, Shaun K. [2 ]
Huang, Tony T. [1 ]
机构
[1] NYU, Dept Biochem & Mol Pharmacol, Sch Med, New York, NY 10016 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA
[3] Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wyb Wyspianskiego 27, PL-50370 Wroclaw, Poland
[4] Arvinas Inc, 5 Sci Pk, New Haven, CT 06511 USA
来源
CELL REPORTS | 2021年 / 36卷 / 13期
关键词
RESPIRATORY-SYNDROME-CORONAVIRUS; RECOGNITION; DOMAIN; COV;
D O I
10.1016/j.celrep.2021.109754
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The SARS-CoV-2 papain-like protease (PLpro) is a target for antiviral drug development. It is essential for processing viral polyproteins for replication and functions in host immune evasion by cleaving ubiquitin (Ub) and ubiquitin-like protein (Ubl) conjugates. While highly conserved, SARS-CoV-2 and SARS-CoV PLpro have contrasting Ub/Ubl substrate preferences. Using a combination of structural analyses and functional assays, we identify a molecular sensor within the S1 Ub-binding site of PLpro that serves as a key determinant of substrate specificity. Variations within the S1 sensor specifically alter cleavage of Ub substrates but not of the Ubl interferon-stimulated gene 15 protein (ISG15). Significantly, a variant of concern associated with immune evasion carries a mutation in the S1 sensor that enhances PLpro activity on Ub substrates. Collectively, our data identify the S1 sensor region as a potential hotspot of variability that could alter host antiviral immune responses to newly emerging SARS-CoV-2 lineages.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Crystal structure of SARS-CoV-2 papain-like protease
    Gao, Xiaopan
    Qin, Bo
    Chen, Pu
    Zhu, Kaixiang
    Hou, Pengjiao
    Wojdyla, Justyna Aleksandra
    Wang, Meitian
    Cui, Sheng
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (01) : 237 - 245
  • [2] Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
    Li, Daoqun
    Luan, Junwen
    Zhang, Leiliang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 538 : 72 - 79
  • [3] The SARS-CoV-2 SSHHPS Recognized by the Papain-like Protease
    Reynolds, Nathanael D.
    Aceves, Nathalie M.
    Liu, Jinny L.
    Compton, Jaimee R.
    Leary, Dagmar H.
    Freitas, Brendan T.
    Pegan, Scott D.
    Doctor, Katarina Z.
    Wu, Fred Y.
    Hu, Xin
    Legler, Patricia M.
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1483 - 1502
  • [4] Crystal structure of SARS-CoV-2 papain-like protease
    Xiaopan Gao
    Bo Qin
    Pu Chen
    Kaixiang Zhu
    Pengjiao Hou
    Justyna Aleksandra Wojdyla
    Meitian Wang
    Sheng Cui
    Acta Pharmaceutica Sinica B, 2021, 11 (01) : 237 - 245
  • [5] Drug Repurposing for the SARS-CoV-2 Papain-Like Protease
    Cho, Chia-Chuan
    Li, Shuhua G.
    Lalonde, Tyler J.
    Yang, Kai S.
    Yu, Ge
    Qiao, Yuchen
    Xu, Shiqing
    Ray Liu, Wenshe
    CHEMMEDCHEM, 2022, 17 (01)
  • [6] Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
    Klemm, Theresa
    Ebert, Gregor
    Calleja, Dale J.
    Allison, Cody C.
    Richardson, Lachlan W.
    Bernardini, Jonathan P.
    Lu, Bernadine G. C.
    Kuchel, Nathan W.
    Grohmann, Christoph
    Shibata, Yuri
    Gan, Zhong Yan
    Cooney, James P.
    Doerflinger, Marcel
    Au, Amanda E.
    Blackmore, Timothy R.
    van der Heden van Noort, Gerbrand J.
    Geurink, Paul P.
    Ovaa, Huib
    Newman, Janet
    Riboldi-Tunnicliffe, Alan
    Czabotar, Peter E.
    Mitchell, Jeffrey P.
    Feltham, Rebecca
    Lechtenberg, Bernhard C.
    Lowes, Kym N.
    Dewson, Grant
    Pellegrini, Marc
    Lessene, Guillaume
    Komander, David
    EMBO JOURNAL, 2020, 39 (18):
  • [7] Targeting SARS-CoV-2 papain-like protease in the postvaccine era
    Ton, Anh-Tien
    Pandey, Mohit
    Smith, Jason R.
    Ban, Fuqiang
    Fernandez, Michael
    Cherkasov, Artem
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (11) : 906 - 919
  • [8] Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro
    Kiba, Yuka
    Tanikawa, Takashi
    Kitamura, Masashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (05) : 965 - 966
  • [9] Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
    Ma, Chunlong
    Wang, Jun
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (02) : 102 - 109
  • [10] SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition
    Ullrich, Sven
    Nitsche, Christoph
    CHEMBIOCHEM, 2022, 23 (19)